Coronavirus disease 2019 (COVID-19) monoclonal antibody treatments

Coronavirus disease 2019 (COVID-19) monoclonal antibody treatments

Medicare Part B (Medical Insurance)

 covers a COVID-19 monoclonal antibody treatment, if all of these apply:

  • You tested positive for COVID-19.
  • You have a mild to moderate case of COVID-19.
  • You’re at high risk of progressing to a severe case of COVID-19 and/or at high risk of requiring hospitalization.
Your costs in Original Medicare

You pay nothing for this treatment during the COVID-19 Public Health Emergency when you get the treatment from a Medicare provider or supplier.

What it is

If you test positive for COVID-19 and have mild to moderate symptoms, these treatments can help fight the disease and keep you out of the hospital. This FDA-authorized treatment involves an infusion of monoclonal antibodies (specifically bamlanivimab, or casirivimab and imdevimab) to treat COVID-19. Health care providers can only administer the infusions consistent with the FDA’s requirements in specific facilities.

Things to know

Return to search results